Key Business Benefits to Attend: • Network with industry-leading experts on drug and antimicrobial material developments • Learn new funding opportunities from BARDA and US National plans, to combat antimicrobial resistance • Understand how the EU Commission's practical approach in R&D can support your business growth • Reinvigorate business models with Project DRIVE-AB and find workable solutions to strengthen drug development • Strengthen your antibiotic pipeline with new insights on microbiome profiling to fight multi-resistant gram negative infections • Hear important discussions on tackling major bottlenecks that hinder development of new antimicrobial drugs with our star panel line-up SMi present the 18th annual conference... 16 - 17 MAR 2016 Holiday Inn Kensington Forum, London, UK Superbugs & Superdrugs PLUS TWO INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPS Tuesday 15th March 2016, Holiday Inn Kensington Forum, London, UK www.superbugssuperdrugs.com Register online or fax your booking form to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711 Pushing financial and collaborative incentives to accelerate clinical success @SMIPHARM WORKSHOP A Rapid Diagnostic Tools for Infectious Diseases Workshop Leader: Sam Whitehouse, Chief Operating Officer, QuantuMDx Group Ltd 8.30am - 12.30pm WORKSHOP B Making a Material Difference to Healthcare Workshop Leader: Andrew Cross, Director, ACT Surfaces Ltd 1.30pm - 5.30pm Chairs for 2016: Richard Bax, Lloyd Czaplewski, Senior Partner, Director, Transcrip Partners Chemical Biology Ventures Ltd Elite International Speakers Include: • Line Matthiessen, MD PhD, Head of Unit Fighting Infectious Diseases and Advancing Public Health, European Commission • Melissa Stundick, Chief, Anti-Infectives Programme, BARDA • Ursula Theuretzbacher, Founder, Centre for Anti-Infective Agents • Prabhavathi Fernandes, President & CEO, Cempra Pharmaceuticals • Ankit Mahadevia, MD , President & CEO, Spero Therapeutics • Eszter Nagy, Co-founder, President and CSO, Arsanis • Jean de Gunzburg, Chief Scientific Officer, Da Volterra • David Cook, Chief Scientific Officer, Blueberry Therapeutics • Conrad Lichtenstein, Chief Scientific Officer, Nemesis Bioscience Ltd • Steven Boakes, Associate Director of Microbiology, Cantab Anti-Infectives BOOK BY 30TH NOVEMBER AND SAVE £400 BOOK BY 18TH DECEMBER AND SAVE £200 BOOK BY 29TH JANUARY AND SAVE £100
Transcript
Key Business Benefits to Attend:• Network with industry-leading experts on drug and antimicrobial
material developments • Learn new funding opportunities from BARDA and US National
plans, to combat antimicrobial resistance • Understand how the EU Commission's practical approach in R&D
can support your business growth • Reinvigorate business models with Project DRIVE-AB and find
workable solutions to strengthen drug development • Strengthen your antibiotic pipeline with new insights on microbiome
profiling to fight multi-resistant gram negative infections• Hear important discussions on tackling major bottlenecks that hinder
development of new antimicrobial drugs with our star panel line-up
SMi present the 18th annual conference...
16 - 17
MAR2016Holiday Inn Kensington Forum, London, UK
Superbugs &Superdrugs
PLUS TWO INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPSTuesday 15th March 2016, Holiday Inn Kensington Forum, London, UK
www.superbugssuperdrugs.com Register online or fax your booking form to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
Pushing financial and collaborative incentives to accelerate clinical success
@SMIPHARM
WORKSHOP A
Rapid Diagnostic Tools for Infectious DiseasesWorkshop Leader:
Sam Whitehouse, Chief Operating Officer, QuantuMDx Group Ltd8.30am - 12.30pm
WORKSHOP B
Making a Material Difference to Healthcare Workshop Leader:
Andrew Cross, Director, ACT Surfaces Ltd 1.30pm - 5.30pm
Chairs for 2016: Richard Bax, Lloyd Czaplewski, Senior Partner, Director, Transcrip Partners Chemical Biology Ventures Ltd
Elite International Speakers Include: • Line Matthiessen, MD PhD, Head of Unit Fighting Infectious Diseases
and Advancing Public Health, European Commission• Melissa Stundick, Chief, Anti-Infectives Programme, BARDA • Ursula Theuretzbacher, Founder, Centre for Anti-Infective Agents• Prabhavathi Fernandes, President & CEO, Cempra Pharmaceuticals• Ankit Mahadevia, MD , President & CEO, Spero Therapeutics• Eszter Nagy, Co-founder, President and CSO, Arsanis• Jean de Gunzburg, Chief Scientific Officer, Da Volterra • David Cook, Chief Scientific Officer, Blueberry Therapeutics • Conrad Lichtenstein, Chief Scientific Officer, Nemesis Bioscience Ltd • Steven Boakes, Associate Director of Microbiology, Cantab
Anti-Infectives
BOOK BY 30TH NOVEMBER AND SAVE £400BOOK BY 18TH DECEMBER AND SAVE £200BOOK BY 29TH JANUARY AND SAVE £100
Register online at: www.sup
Dear Colleagues
It is with great pleasure that we welcome you to participate in the 18th Annual Superbugs & Superdrugs conference taking place on16th -17th March 2016, Central London, UK.
Antimicrobial resistance is clearly a serious global threat. To combat potential epidemic, requires both industry and governmentcollaboration on an international level in antibiotics R&D investments, preventive measures and emergency response. As newresistance mechanisms rapidly spread throughout the developed and developing nations, this is putting our existing antibiotic pipelineunder greater higher risk of failing to resolve many standard medical treatments, as well as compromising our achievements in modernstandard medicine including cancer therapeutics and surgery. To curb an uncontrollable outbreak ‘storm’, we urge committed actionand international stewardship from the industry to drive anti-superbugs and superdrug developments.
We are delighted to chair this annual industry meeting in 2016 again, which will gather a high level of international experts and projectdecision makers in a timely opportunity to discuss ongoing challenges and lay the foundation for innovations that will enhance thesecurity and R&D projects for novel therapies in anti-infectives.
Please take time to peruse the conference agenda which has been drafted with great care to give you the very best opportunity tobenchmark and learn from subject matter experts in infectious diseases, health economics and advanced technologies and solutions.Networking and learning with our peers is the secret to improving the drug development pipeline. With practical case studies andinteractive roundtables, there is confidence that we will be able to crack the ‘chicken or the egg’ problem.
Yours Sincerely,
Richard Bax, Senior Partner, Transcrip Partners Lloyd Czaplewski, Director, Chemical Biology Ventures Ltd
Workshop Overview:This workshop will show attendees how complexdiagnostics can be delivered in minutes for a fewdollars in any setting across the globe using portabledevices. We will also evaluate key definitive factorsof disease diagnosis & drug resistance testing andmobile data connection.
Why you should attend: • Gain valuable practise of understanding what
factors to work with and look out for in diagnosing infections and resistant strains
• Understand the dangers of misdiagnosis and thefine lines between familiar strains and symptoms
• Learn how our models can circumvent HAI’s andperform in disease management and drugresistance monitoring through geo-stamped data
About the workshop leader: Sam is chief operating officer ofQuantuMDx Group Ltd and the inventorof underlying DNA extraction chemistriescurrently being commercialised by thecompany. With 14 years biotech
experience including, development ofcardiovascular medical devices, polymer drugsystems, coating technologies, industrial researchand managing a large portfolio of academic-industry biotech collaborations. Sam has a history of
commercialising basic research, licensing andtechnology transfer from SME’s and MNC’s.Currently he oversees operations in the UK, USA andSingapore.
About the Organisation: QuantuMDx is passionateabout playing a role inaddressing humanitarian
health challenges and strongly believes that qualitymolecular diagnostics is an innate human right andas such should be provided to every man, womanand child on this planet, regardless of race, countryor creed.
Our mission is to develop Q-POC™ our novelhandheld device to provide access to goldstandard molecular diagnostic testing, in minutes, tothe billions of people in poorer nations who urgentlyneed a rapid, cheap and accurate way ofdiagnosing disease and drug resistance. This will helpaddress the humanitarian health challenges such asmalaria, TB, HIV and cancer and, in time, support theeradication of some diseases by prescribing the rightdrug, first time. Furthermore, we will develop Q-POC™ to meet the strict regulatory requirementsthat will enable it to become the diagnostic deviceof choice for all health professionals, police, rapidresponders, vets and farmers.
Workshop Overview:How can copper touch surfaces improve patientoutcomes and provider finances? Is this a viableproposition for healthcare today? Why copper - howdoes copper differ from other antimicrobialsurfaces? What research backs its use? Which itemsto consider? What products and materials areavailable?
Drawing on feedback and experience from previousinstallations, as well as current guidelines, thisworkshop will examines the evidence, cost-paybackand practical implementation concerning thestrategic deployment of copper touch surfaces.
Why you should attend: Healthcare is under pressure to innovate, improvepatient outcomes and reduce costs. This workshopexplores a simple and low-risk intervention, and itspotential impact on HCAI rates and AntimicrobialResistance.
About the workshop leader: Andrew offers a mixture of technical,practical and commercial experience,and works closely with engineers,architects / designers, construction
professionals, healthcare scientists and clinical teamsto prompt a reevaluation of materials used inhealthcare settings.
About the Organisation: Working in close partnership withapproved suppliers and healthcareprofessionals, ACT Surfaces provide acomprehensive “end to end” service
of advice and products. Strategic use ofAntimicrobial Copper Touch Surfaces enableshealthcareproviders to improve patient outcomes and optimisepayback. The goal is to help healthcare professionalsselect the right products and materials for theirparticular setting and infection control needs.
TWO INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPSTuesday 15th March 2016, Holiday Inn Kensington Forum, London, UK
Programme
8.30 Registration
9.00 Opening remarks and introductions
9.10 Session 1: Diagnostics • Tracking emerging infections and outbreaks:
Current pitfalls and areas to address • State-of-the-art diagnostic tools: What to
disease from broad symptoms • The definitive factors of diagnosing disease
10.30 Afternoon Tea
11.00 Session 3: Mobile applications for differentenvironments
• Diagnosing in different settings: Case studyand evaluation
• Data access and transfer
11.40 Session 4: Future work and progress • Challenges of diagnosis: mutation factors
and strain differentiation • Discussion
12.20 Closing remarks
12.30 Close of workshop
Making a material difference to Healthcare 1.30pm – 5.30pm Workshop Leader: Andrew Cross, Director, ACT Surfaces Ltd
Programme1.30 Registration2.00 Opening remarks and introductions2.10 Session 1: • Two major issues in healthcare today
- HCAIs and AMR2.50 Session 2: • The role of the patient environment in
acquisition of infection and spread of AMR3.30 Afternoon Tea4.00 Session 3: • Evaluating Antimicrobial efficacy for touch surfaces • The evidence for copper4.40 Session 4: • Cost vs Benefit - the YHEC research • Q&A session, practial demonstration5.20 Closing remarks 5.30 Close of workshop
Rapid Diagnostic Tools for Infectious Diseases 8.30am – 12.30pm Workshop Leader: Sam Whitehouse, Chief Operating Officer, QuantuMDx Group Ltd
Superbugs & Superdrugs Day One | Wednesday 16th March 2016
Models for Successful Partnerships and Clinical Management
9.10 OPENING ADDRESS: Current status and future prospects•Progress in R&D and drug regulation•What is happening in big Pharma•New economic models•What needs to be done now Richard Bax, Senior Partner, Transcrip Partners
9.50 Extending portfolio partnerships to strengthen the antibioticpipeline•Ongoing and future research and development
partnerships•BARDA’s efforts to address goals in the U.S. National Plan to
Combat Antibiotic Resistant infections•Establishing a biopharmaceutical incubator to meet short
and long term goals •BARDA funding opportunities Melissa Stundick, Chief, Anti-Infectives Programme, BARDA
10.30 Morning Coffee
10.50 Developing an antibiotic with potential for use in multipletherapeutic indications •Case study: Stage 3 clinical update outcomes and
response •International collaboration for successful worldwide
commercialisation Prabhavathi Fernandes, President & CEO,Cempra Pharmaceuticals
11.30 Making a material difference to healthcare•Two issues: HCAIs and AMR•The role of touch surfaces in the acquisition of infection
and spread of AMR•Evaluation of antimicrobial efficacy•Evidence for copper touch surfaces and YHEC payback
modelAndrew Cross, Director, ACT Surfaces Ltd
12.10 Networking Lunch
1.10 KEYNOTE ADDRESS: Fighting global epidemics and progressing public- private partnerships•State of play of the EU action plan on AMR •How is R&D being supported in a practical sense?Line Matthiessen, MD PhD, Head of Unit Fighting InfectiousDiseases and Advancing Public Health, EuropeanCommission
1.50 Project DRIVE-AB: New partners and developments •Prioritising problem areas and future development •New models and action plans •Clinical practice strategies to aid the development pipeline Ursula Theuretzbacher, Founder, Centre for Anti-Infective Agents
Progressive R&D and Clinical Trials
2.50 New insights of pathogen – host interactions and EU project -INFECT•Systems medicine approach to understand pathogenic
mechanisms•New in vitro models to understand drug resistance at the
tissue site of infection •Accelerating drug development and diagnostic tools
through INFECTAnna Norrby-Teglund, Professor, Head of Center forInfectious Medicine, Karolinska Institutet
3.30 Afternoon Tea
4.00 Monoclonal antibody-based approaches to fight severebacterial infections •New paradigm to prevent and treat severe
Staphyloccocus aureus infections •mAb products targeting MDR Gram negative infections •Companion diagnostics for introduction of targeted
therapies and support MDR infectious disease control Eszter Nagy, Co-founder, President and CSO, Arsanis
4.40 Application of whole genome sequencing to public health•Whole genome sequencing as a gold standard approach
for molecular strain typing •Outbreak investigations using whole genome sequencing •Case study: Pattern/ type assignment •Future perspectives in public health Georgia Kapatai, Bioinformatician, Public Health England
5.20 Rapid diagnostic tools •Advances in molecular diagnostic devices: Sample
preparation and PCR •Case study: Rapid diagnosis of drug-resistant forms of TB •Optimising speed and accuracy for rapid detection •Sample to result processes – fluidics and microfluidicsSam Whitehouse, Chief Operating Officer,QuantuMDx Group Ltd
6.00 PANEL DISCUSSION: Tackling the major bottlenecks that hinder development of new antibacterial drugs•Sample preparation, bottle necks in work flows•True point of care – field based (not laboratory) testing•Multifaceted infection control programmes and cost efficiency•Is the biotech sector the forgotten partner in developing
new treatments for AMR?•Regulatory environment for non-traditional therapies: Is a
new paradigm needed?•Racing “The Red Queen”: How can we win the arms race?•Is giving taxpayer money to pharmaceutical companies
the best way of stimulating the development of new anti-infectives?
Panel leader: Richard Bax, Senior Partner, Transcrip PartnersPanelists:Prabhavathi Fernandes, President & CEO, CempraPharmaceuticalsEszter Nagy, Co-founder, President and CSO, ArsanisSam Whitehouse, Chief Operating Officer, QuantuMDx Group LtdConrad Lichtenstein, Chief Scientific Officer, Nemesis BioscienceDavid Cook, Chief Scientific Officer, Blueberry TherapeuticsJean de Gunzburg, Chief Scientific Officer, Da Volterra
6.40 Chairman's Closing Remarks and Close of Day One
perbugssuperdrugs.com • Alternatively fax your registration to +44 (0)870 9090 712
Superbugs & SuperdrugsDay Two | Thursday 17th March 2016
8.30 Registration & Coffee
9.00 Chairman's Opening Remarks
Lloyd Czaplewski, Director, Chemical Biology Ventures Ltd
Strengthening the Antibiotic Pipeline
9.10 OPENING ADDRESS: What if there are no new antibiotics?
•Highlights of a review into the alternatives to antibiotics
•What can we expect within the next 10 years and how
much will it cost?
•Why antimicrobial resistance must become a BIG science
Lloyd Czaplewski, Director, Chemical Biology Ventures Ltd
•Development of NCE’s and combination methods that
successfully penetrate the outer bacterial membrane
•Strategic collaborations that have strengthened product
pipeline
•HTS and characterization of MvfR inhibitors and correlating
clearance times of resistant strains with potent inhibitors
Ankit Mahadevia, MD, President & CEO, Spero Therapeutics
10.30 Morning Coffee
10.50 Antibiotic resurrection: Taking the path of least resistance
•Achieving antibiotic sensitivity and resistance prevention
•Nemesis Symbiotics: Delivery options for companion
therapeutics
•Clinical applications
Conrad Lichtenstein, Chief Scientific Officer,
Nemesis Bioscience Ltd
11.30 Building a pipeline and framework for developing novel anti-
microbial drugs
•Are there opportunities beyond small molecule antibiotics?
•Building partnerships and collaborations to drive innovation
•Challenges
•Economics: The elephant in the room?
David Cook, Chief Scientific Officer, Blueberry Therapeutics Ltd
12.10 Networking Lunch
1.10 Clinical development of broad-spectrum anti-infective
treatment drugs
•Protecting the human microbiome – what do we know?
New frontiers microbiome profiling
•Narrow spectrum vs broad-spectrum antibiotics on the
microbiome
•Pre-clinical to clinical trial evaluation
Jean de Gunzburg, Chief Scientific Officer, Da Volterra
1.50 Determining preclinical PK/PD relationships for faster and
accurate drug development
•Efficiently modelling PK and PD for optimising dosage
requirements of new and existing drugs
•Regulatory recommendations of PK/PD relationships for
antibacterial agents
•Preclinical models of PK/PD results and human translatability
•Individualised treatment and controlling extreme variability
William Hope, Professor, Antimicrobial Pharmacodynamics
and Therapeutics, University of Liverpool
Smart Antimicrobials and Pioneering Approaches
2.30 Antimicrobial peptides as viable alternatives
•Pros and Cons of antimicrobial peptides
•Current pipeline
•Cantab Anti-infectives experience with lantibiotics and
polymyxins.
Steven Boakes, Associate Director of Microbiology,
Cantab Anti-Infectives
3.10 Afternoon Tea
3.30 The use of combination antibiotic therapy
•History of antibiotic combinations
•Rationale for combination therapy
•Advantages / disadvantage of combining antibiotics
•Testing regimens for combination therapy
William Weiss, Director, Pre-Clinical Services,
UNT Health Science Center
4.10 Hyperbaric oxygen treatment as an adjunctive treatment to
infectious diseases and its synergistic effects
•Mechanisms of HBO2 therapy in underpinning improved
immunity and increased antibiotic activity
•A retrospective analysis of patients who received HBO
treatment and outcomes
•Synergistic effects to improve clinical outcomes in patients
post-surgery
Ole Hyldegaard, Medical Director, Associate Professor,
University Hospital of Copenhagen-Rigshospitalet
4.50 Microbiota host interactions as a starting point for
antimicrobial strategies
•Experimental microbiota platforms
•Next generation sequencing
•Analysing AMR development through metagenomics
•Host pathogen/microbiome interactions
Frank Schuren, Senior Scientist Microbiology, TNO
5.20 Chairman’s Closing Remarks and Close of Day Two
2 or call +44 (0)870 9090 711
SPONSORSHIP AND EXHIBITION OPPORTUNITIESSMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy.
Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussionspecific to your industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call:
Pharmaceutical Microbiology20th - 21st January 2016Holiday Inn Kensington Forum,London, UK
Social Media In The Pharmaceutical Industry20th - 21st January 2016Holiday Inn Kensington Forum,London, UK
Pre-Filled Syringes27th - 28th January 2016Copthorne Tara Hotel, London, UK
FEBRUARY
Parallel Trade8th - 9th February 2016Holiday Inn Kensington Forum,London, UK
Advances and Progress in Drug Design15th - 16th February 2016Holiday Inn Kensington Forum,London, UK
RNAi Therapeutics15th - 16th February 2016Holiday Inn Kensington Forum,London, UK
MARCH
Superbugs & Superdrugs- A Focus on Antibacterials16th - 17th March 2016Holiday Inn Kensington Forum,London, UK
Paediatric Clinical Trials16th - 17th March 2016Holiday Inn Kensington Forum,London, UK
APRIL
Asthma & COPD11th - 12th April 2016Holiday Inn Kensington Forum,London, UK
Controlled Release18th - 19th April 2016Holiday Inn Regents Park,London, UK
Adaptive Designs18th - 19th April 2016Holiday Inn Regents Park,London, UK
Pre Filled Syringes USA25th - 26th April 2016Renaissance Woodbridge,New Jersey, USA
Lyophilisation USA27th - 28th April 2016Renaissance Woodbridge,New Jersey, USA
Want to know how you can get involved? Interested in promoting your services to this market? Contact Teri Arri, SMi Marketing on +44 (0) 207 827 6162 or email: [email protected]
FAX your booking form to +44 (0) 870 9090 712PHONE on +44 (0) 870 9090 711
POST your booking form to: Events Team, SMi Group Ltd, 2nd FloorSouth, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK
SUPERBUGS & SUPERDRUGS Conference: Wednesday 16th & Thursday 17th March 2016, Holiday Inn Kensington Forum, London, UK
Workshops: Tuesday 15th March 2016, London, UK
4 WAYS TO REGISTERwww.superbugssuperdrugs.com
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email [email protected]
Payment: If payment is not made at the time of booking, then an invoice will be issued and must bepaid immediately and prior to the start of the event. If payment has not been received then creditcard details will be requested and payment taken before entry to the event. Bookings within 7 daysof event require payment on booking. Access to the Document Portal will not be given until paymenthas been received.Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, anotherdelegate to take your place at any time prior to the start of the event. Two or more delegates maynot ‘share’ a place at an event. Please make separate bookings for each delegate.Cancellation: If you wish to cancel your attendance at an event and you are unable to send asubstitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providingthat cancellation is made in writing and received at least 28 days prior to the start of the event.Regretfully cancellation after this time cannot be accepted. We will however provide theconferences documentation via the Document Portal to any delegate who has paid but is unableto attend for any reason. Due to the interactive nature of the Briefings we are not normally able toprovide documentation in these circumstances. We cannot accept cancellations of orders placedfor Documentation or the Document Portal as these are reproduced specifically to order. If we haveto cancel the event for any reason, then we will make a full refund immediately, but disclaim anyfurther liability.Alterations: It may become necessary for us to make alterations to the content, speakers, timing,venue or date of the event compared to the advertised programme.Data Protection: The SMi Group gathers personal data in accordance with the UK Data ProtectionAct 1998 and we may use this to contact you by telephone, fax, post or email to tell you about otherproducts and services. Unless you tick here □ we may also share your data with third parties offeringcomplementary products or services. If you have any queries or want to update any of the data thatwe hold then please contact our Database Manager [email protected] or visitour website www.smi-online.co.uk/updates quoting the URN as detailed above your address on theattached letter.
Unique Reference Number
Our Reference LVP-163
Terms and Conditions of Booking
DELEGATE DETAILSPlease complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:I agree to be bound by SMi's Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
VENUE Holiday Inn Kensington Forum, 97 Cromwell Rd, London SW7 4DN, UK
□ Please contact me to book my hotelAlternatively call us on +44 (0) 870 9090 711, email: [email protected] or fax +44 (0) 870 9090 712
□ Book by 30th November 2015 to receive £400 off the conference price□ Book by 18th December 2015 to receive £200 off the conference price□ Book by 29th January 2016 to receive £100 off the conference price
EARLY BIRDDISCOUNT
Payment must be made to SMi Group Ltd, and received before the event, by one ofthe following methods quoting reference P-163 and the delegate’s name. Bookingsmade within 7 days of the event require payment on booking, methods of paymentare below. Please indicate method of payment:
□ UK BACS Sort Code 300009, Account 00936418□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU Swift (BIC): LOYDGB21013, Account 00936418 IBAN GB48 LOYD 3000 0900 9364 18□ Cheque We can only accept Sterling cheques drawn on a UK bank.□ Credit Card □ Visa □ MasterCard □ American Express All credit card payments will be subject to standard credit card charges.
Card No: □□□□ □□□□ □□□□ □□□□Valid From □□/□□ Expiry Date □□/□□CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:I agree to be bound by SMi's Terms and Conditions of Booking.
Card Billing Address (If different from above):
DOCUMENTATIONI cannot attend but would like to purchase access to the following DocumentPortal/paper copy documentation Price Total□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80□ The Conference Presentations – paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
PAYMENT
VATVAT at 20% is charged on the attendance fees for all delegates. VAT is also charged onDocument portal and literature distribution for all UK customers and for those EU Customersnot supplying a registration number for their own country here.______________________________________________________________________________________________
CONFERENCE PRICESI would like to attend: (Please tick as appropriate) Fee Total□ Conference & 2 Workshops £2697.00 + VAT £3236.40□ Conference & 1 Workshop AM □ PM □ £2098.00 + VAT £2517.60□ Conference only £1499.00 + VAT £1798.80□ 1 Workshop only AM □ PM □ £599.00 + VAT £718.80□ 2 Workshops £1198.00 + VAT £1437.60
PROMOTIONAL LITERATURE DISTRIBUTION □ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80The conference fee includes refreshments, lunch, conference papers, and access to theDocument Portal. Presentations that are available for download will be subject todistribution rights by speakers. Please note that some presentations may not be availablefor download. Access information for the document portal will be sent to the e-mailaddress provided during registration. Details are sent within 24 hours post conference.
